MX2023002774A - Sales y cristales. - Google Patents
Sales y cristales.Info
- Publication number
- MX2023002774A MX2023002774A MX2023002774A MX2023002774A MX2023002774A MX 2023002774 A MX2023002774 A MX 2023002774A MX 2023002774 A MX2023002774 A MX 2023002774A MX 2023002774 A MX2023002774 A MX 2023002774A MX 2023002774 A MX2023002774 A MX 2023002774A
- Authority
- MX
- Mexico
- Prior art keywords
- tetrahydropyrazolo
- freebase
- benzodiazepine
- methyl
- solid forms
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- YAHHFPJGDOWLGU-UHFFFAOYSA-N 1-methyl-5,10-dihydro-4H-pyrazolo[4,3-c][1,5]benzodiazepine Chemical compound Cn1ncc2CNc3ccccc3Nc12 YAHHFPJGDOWLGU-UHFFFAOYSA-N 0.000 abstract 3
- 239000012458 free base Substances 0.000 abstract 3
- 239000007787 solid Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a formas sólidas de base libre de 1-metil-1,4,5,10-tetrahidropirazolo[3,4-b][1,5]benzodiazepina que poseen propiedades farmacocinéticas deseables, como, por ejemplo, higroscopicidad baja y estabilidad térmica mejorada. Estas formas sólidas incluyen una forma sólida de base libre de 1-metil-1,4,5,10-tetrahidropirazolo[3,4-b][1,5]benzodiazepina y sal de fosfato y de L-tartrato de la base libre de 1-metil-1,4,5,10-tetrahidropirazolo[3,4-b][1,5]benzodiazepina. También se describen las composiciones farmacéuticas, medicamentos y equipos que comprenden dichas formas sólidas. También se proporcionan métodos para utilizar dichas formas para tratar varias enfermedades, padecimientos y trastornos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020903196A AU2020903196A0 (en) | 2020-09-07 | Salts and crystals | |
| PCT/AU2021/051033 WO2022047548A1 (en) | 2020-09-07 | 2021-09-07 | Salts and crystals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002774A true MX2023002774A (es) | 2023-04-03 |
Family
ID=80492327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002774A MX2023002774A (es) | 2020-09-07 | 2021-09-07 | Sales y cristales. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240287074A1 (es) |
| EP (1) | EP4211138A4 (es) |
| JP (1) | JP2023540587A (es) |
| KR (1) | KR20230066050A (es) |
| CN (1) | CN116745293A (es) |
| AU (1) | AU2021336662A1 (es) |
| CA (1) | CA3191811A1 (es) |
| IL (1) | IL301181A (es) |
| MX (1) | MX2023002774A (es) |
| WO (1) | WO2022047548A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1512687A1 (en) * | 2003-09-05 | 2005-03-09 | Ferring B.V. | Piperazines as oxytocin agonists |
| WO2017004674A1 (en) * | 2015-07-06 | 2017-01-12 | The University Of Sydney | Therapeutic compounds and compositions for treating social disorders and substance use disorders |
| EP4025221A4 (en) * | 2019-09-06 | 2024-01-03 | Kinoxis Therapeutics Pty Ltd | TREATMENT OF OPIOID WITHDRAWAL |
-
2021
- 2021-09-07 AU AU2021336662A patent/AU2021336662A1/en active Pending
- 2021-09-07 EP EP21863128.1A patent/EP4211138A4/en active Pending
- 2021-09-07 MX MX2023002774A patent/MX2023002774A/es unknown
- 2021-09-07 JP JP2023515354A patent/JP2023540587A/ja active Pending
- 2021-09-07 IL IL301181A patent/IL301181A/en unknown
- 2021-09-07 WO PCT/AU2021/051033 patent/WO2022047548A1/en active Application Filing
- 2021-09-07 KR KR1020237011768A patent/KR20230066050A/ko active Search and Examination
- 2021-09-07 US US18/044,190 patent/US20240287074A1/en active Pending
- 2021-09-07 CA CA3191811A patent/CA3191811A1/en active Pending
- 2021-09-07 CN CN202180075241.0A patent/CN116745293A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4211138A4 (en) | 2024-09-18 |
| EP4211138A1 (en) | 2023-07-19 |
| AU2021336662A1 (en) | 2023-05-04 |
| CA3191811A1 (en) | 2022-03-10 |
| US20240287074A1 (en) | 2024-08-29 |
| JP2023540587A (ja) | 2023-09-25 |
| IL301181A (en) | 2023-05-01 |
| CN116745293A (zh) | 2023-09-12 |
| WO2022047548A1 (en) | 2022-03-10 |
| KR20230066050A (ko) | 2023-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550881A1 (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| MD3555097T2 (ro) | Compuși imidazo[4,5-d]pirolo[2,3-b]piridină ca inhibitori ai kinazelor Janus | |
| JP5409783B2 (ja) | 置換ｎ−オキシドピラジン誘導体 | |
| MX2020007959A (es) | Derivados de 2h-indazol e inhibidores de cdk4 y cdk6 y sus usos terapeuticos. | |
| MX2017013219A (es) | Sales de maleato de un inhibidor de b-raf quinasa, formas cristalinas, metodos de preparacion y por consiguiente sus usos. | |
| WO2015011084A1 (de) | Substituierte dihydropyrido[3,4-b]pyrazinone als duale inhibitoren von bet-proteinen und polo-like kinasen | |
| JP2011520832A5 (es) | ||
| MX2023012187A (es) | Derivados de fosforo como nuevos inhibidores de sos1. | |
| TW201200518A (en) | Heterocyclic inhibitors of histamine receptors for the treatment of disease | |
| UA71610C2 (uk) | Біциклічні гетероцикли та фармацевтична композиція на їх основі | |
| MX2010006748A (es) | Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2. | |
| US20190135807A1 (en) | Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same | |
| MX2021002051A (es) | Imidazo[1,2-b]piridaziinas como inhibidores de trk. | |
| TW201014854A (en) | Substituted pyrimido isoquinoline derivatives | |
| WO2020247298A3 (en) | 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
| BRPI0718519A2 (pt) | 8-piperidinil-2-pridinil-pirimido-[1,2-a]piridimin-6-ona substituída e derivados da 8-piperidinil-2-pirimidinil-pirimido[1,2-a]pirimidin-6-ona | |
| PE20212113A1 (es) | Inhibidores de moleculas pequenas de la familia de quinasas jak | |
| CR20220160A (es) | Derivados de piridazin-3(2h)-ona fusionados con azol | |
| JOP20210275A1 (ar) | مشتقات 3-أمينو-4h-بنزو[e][4,2,1]ثيادايازين 1,1-داي أكسيد كمثبطات لـ mrgx2 | |
| MX2021009371A (es) | Formulaciones que comprenden inhibidores de proteina cinasa heterociclicos. | |
| MX2022007518A (es) | Derivados bencimidazol. | |
| NZ761680A (en) | Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors | |
| PA8592801A1 (es) | Derivados biciclicos para el tratamiento del crecimiento celular anormal | |
| MX2023002774A (es) | Sales y cristales. | |
| MX2022004878A (es) | Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos. |